Pull to refresh
Logo
Researchers find drug combo that slows treatment-resistant prostate cancer

Researchers find drug combo that slows treatment-resistant prostate cancer

New Capabilities

Michigan team reverses the cell identity switch that lets prostate tumors evade treatment

Today: JCI Insight publishes two-drug combination study

Overview

Updated 1 hour ago

Some prostate cancer tumors survive treatment by changing what they are—losing glandular identity and adopting stem-cell-like traits, a process called transdifferentiation. A University of Michigan team showed in JCI Insight that combining two drug classes reverses many of those changes and sharply slows tumor growth in mice.

Treatment-resistant prostate cancer has few options once tumors stop responding to hormone therapy. The combination approach targets the identity switch itself, and the team plans to develop clinical trials to test it in patients.

Why it matters

Treatment-resistant prostate cancer has few options today. This drug combo targets the resistance mechanism itself, potentially adding years for patients who run out of choices.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

2
Drug classes combined
BET bromodomain inhibitors plus DNA methyltransferase (DNMT) inhibitors, tested together for the first time.
2
Genes tied to resistance
Loss of TP53 and RB1 drives the cell identity switch that lets tumors evade treatment.
Preclinical
Research stage
Results come from prostate cancer cell lines and mouse models; human trials have not yet started.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

June 2026 September 2026

2 events Latest: Today
  1. JCI Insight publishes two-drug combination study

    Today Publication

    University of Michigan researchers show BET bromodomain and DNMT inhibitors together reverse transdifferentiation and slow tumor growth in mice.

  2. PIM1-targeting drug shows promise in resistant prostate cancer

    Research finding

    A separate research team reports that degrading PIM1 with a PROTAC molecule increases oxidative stress in prostate cancer cells and improves cell death.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2015-2017

CDK4/6 inhibitors for hormone-resistant breast cancer (2015-2017)

Palbociclib, ribociclib, and abemaciclib were approved after trials showed that adding a CDK4/6 inhibitor to hormone therapy extended progression-free survival in advanced breast cancer patients whose tumors had developed resistance.

Then

Combination therapy became the standard of care for metastatic HR-positive, HER2-negative breast cancer.

Now

Demonstrated that blocking the specific pathways resistance mechanisms rely on can meaningfully extend survival.

Why this matters now

Shows the path from preclinical discovery to clinical standard of care when a second drug targets the resistance mechanism directly.

2015

Osimertinib for EGFR T790M-resistant lung cancer (2015)

After first-generation EGFR inhibitors stopped working because of a new resistance mutation (T790M), osimertinib was developed to target that specific resistance mechanism. Trials showed dramatic response rates in patients who had progressed on earlier drugs.

Then

Osimertinib became standard second-line therapy, then moved to first-line treatment.

Now

Established that understanding a specific resistance mechanism allows the development of drugs that hit it directly.

Why this matters now

Like the Michigan approach, it turns knowledge of the resistance mechanism into a targeted treatment strategy, rather than just managing symptoms of progression.

Documented since the 1990s

Neuroendocrine transformation of prostate cancer (clinical phenomenon)

Under prolonged androgen deprivation, a subset of prostate adenocarcinomas transform into small cell neuroendocrine carcinomas—an aggressive form with a fundamentally different cellular identity. This is the clinical manifestation of lineage plasticity, the same phenomenon the new study targets.

Then

Patients who transform typically progress rapidly on hormone therapy and have poor survival.

Now

Established the concept that prostate cancer cells can change identity under treatment pressure, transforming how researchers think about resistance.

Why this matters now

The transdifferentiation in the new study is the same biological phenomenon, now addressed mechanistically with drugs rather than just observed.

Sources

(4)